Impax Laboratories Inc. (IPXL) Tops Q2 EPS by 16c

Impax Laboratories Inc. (NASDAQ: IPXL) reported Q2 EPS of $0.60, $0.16 better than the analyst estimate of $0.44. Revenue for the quarter came in at $166.5 million versus the consensus estimate of $162.03 million.

For earnings history and earnings-related data on Impax Laboratories Inc. (IPXL) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• CAE, Inc. (CAE) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY27 EPS Guidance
• SeaStar Medical (ICU) Misses Q1 EPS by 4c
• Denison Mines Corp. (DNN) Tops Q2 EPS by 4c